newsfilter
← Latest News
GlobeNewswire·

CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

Presentation and publication of clinical and biomarker data, regulatory developments, and 100mg BID dosing regimen support advancement of the neflamapimod clinical development program in dementia with Lewy bodies